India Cell and Gene Therapy Market

India Cell and Gene Therapy Market Overview:

The India cell and gene therapy market size reached USD 710.91 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,513.14 Million by 2033, exhibiting a growth rate (CAGR) of 15.10% during 2025-2033. Rising prevalence of genetic disorders, growing investments in biotechnology, regulatory support for advanced therapies, increasing clinical trials, demand for personalized medicine, expanding healthcare infrastructure, technological advancements in gene editing, availability of skilled researchers, collaborations between academia and industry, and a surge in stem cell research are key drivers shaping market growth.

India Cell and Gene Therapy Market Trends:

Expansion of Domestic Manufacturing and Infrastructure

India is witnessing significant investment in domestic cell and gene therapy manufacturing to reduce dependency on imports. Leading biotechnology firms and pharmaceutical companies are establishing Good Manufacturing Practice (GMP)-compliant facilities to produce vector-based and autologous therapies. Government initiatives are further encouraging indigenous production. This expansion is expected to improve affordability, streamline regulatory approvals, and accelerate market access for innovative therapies. Additionally, contract development and manufacturing organizations (CDMOs) are gaining traction as key players in supporting large-scale production. The establishment of dedicated cell therapy centers and regulatory-backed infrastructure projects positions India as a competitive hub for cell and gene therapy innovation in the Asia-Pacific region. For instance, in April 2024, the Government of India (GoI) launched country’s first homegrown gene therapy for cancer, CAR-T cell therapy, at IIT Bombay. Developed in collaboration with Tata Memorial Hospital and ImmunoACT, it is the world’s most affordable CAR-T therapy. The initiative aligns with ‘Make in India’ and ‘Atmanirbhar Bharat,’ making advanced cancer treatment accessible. The therapy, a major medical breakthrough, leverages academia-industry partnerships, reinforcing India’s role in cutting-edge healthcare innovation and technological self-reliance.

Increasing Clinical Trials and Regulatory Advancements

India is emerging as a strategic location for clinical trials in cell and gene therapy, driven by a large patient pool and cost-effective research capabilities. The Central Drugs Standard Control Organization (CDSCO) is implementing structured regulatory pathways, streamlining approval processes for experimental therapies. The introduction of accelerated approvals for orphan diseases and rare genetic disorders is further fueling trial activity. Additionally, collaborations between Indian research institutions and global biotech firms are facilitating multicenter trials, leading to faster clinical validation of therapies. As regulatory frameworks evolve to align with international standards, India’s attractiveness as a research and development hub for advanced therapeutic medicinal products (ATMPs) is increasing, creating an ecosystem conducive to innovation and commercialization. For instance, in February 2024, India approved its first homegrown CAR T-cell therapy, NexCAR19. Developed by ImmunoACT, a spin-off of IIT Bombay, it was tested in 64 patients with lymphoma or leukemia, achieving a 67% response rate. The therapy, licensed for manufacturing in Mumbai, aims to treat 1,200 patients annually. Collaboration with NCI scientists helped refine its development, ensuring accessibility in India’s healthcare system.

India Cell and Gene Therapy Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region/country level for 2025-2033. Our report has categorized the market based on therapy type, indication, delivery mode, and end user.

Therapy Type Insights:

• Cell Therapy
  • Stem Cell
    • Pluripotent Stem Cell
    • Cancer Stem Cell
    • Adult Stem Cell
  • Non-Stem Cell
    • T-Cell
    • Natural Killer Cell
    • Others
• Gene Therapy

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes cell therapy (stem cell (pluripotent stem cell, cancer stem cell, and adult stem cell) and non-stem cell (t-cell, natural killer cell, and others)) and gene therapy.

Indication Insights:

• • Cardiovascular Disease
  • Oncology Disorder
  • Genetic Disorder
  • Infectious Disease
  • Neurological Disorder
  • Others

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes cardiovascular disease, oncology disorder, genetic disorder, infectious disease, neurological disorder, and others.

Delivery Mode Insights:

• In-Vivo
• Ex-Vivo

A detailed breakup and analysis of the market based on the delivery mode have also been provided in the report. This includes in-vivo and ex-vivo.

End User Insights:

• Hospitals
• Cancer Care Centers
• Pharmaceuticals and Biotechnology Companies
• Others

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, cancer care centers, pharmaceuticals and biotechnology companies, and others.

Regional Insights:

• North India
• South India
• East India
• West India

The report has also provided a comprehensive analysis of all the major regional markets, which include North, South, East, and West India.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

India Cell and Gene Therapy Market News: 

• In January 2025, Immuneel Therapeutics launched Qartemi, India's second CAR T-cell therapy for B-cell non-Hodgkin lymphoma (B-NHL). With 120,000 new blood cancer cases and 70,000 deaths annually, this therapy offers a breakthrough alternative to chemotherapy. Immuneel initiated clinical trials in 2022 and has partnered with major hospitals, ensuring accessibility. Licensed from Hospital Clínic de Barcelona, Qartemi meets global standards while being produced in Bangalore at lower costs. The therapy enhances India’s role in advanced cancer treatments.
• In February 2025, Miltenyi Biotec inaugurated India’s first cell and gene therapy Centre of Excellence (CoE) in Hyderabad, spanning 1,800 sqm in Genome Valley. The Miltenyi Innovation and Technology Centre (MITC) will advance biomedical research, offering cutting-edge MACS instruments, therapy development platforms, and training programs. The facility aims to accelerate cell and gene therapy innovations, particularly for cancer treatment, strengthening Telangana’s biotech ecosystem.
• In June 2024, AIIMS researchers announced that they are developing gene therapy for sickle cell disease using CRISPR-Cas9, with expected breakthroughs by January 2025. The therapy targets India's high disease burden, especially among Scheduled Tribes. The Union Tribal Affairs Ministry anticipates promising laboratory results, marking a significant step toward an effective treatment.

India Cell and Gene Therapy Market Report Coverage:

Key Questions Answered in This Report:

• How has the India cell and gene therapy market performed so far and how will it perform in the coming years?
• What is the breakup of the India cell and gene therapy market on the basis of therapy type?
• What is the breakup of the India cell and gene therapy market on the basis of indication?
• What is the breakup of the India cell and gene therapy market on the basis of delivery mode?
• What is the breakup of the India cell and gene therapy market on the basis of end user?
• What are the various stages in the value chain of the India cell and gene therapy market? 
• What are the key driving factors and challenges in the India cell and gene therapy market?
• What is the structure of the India cell and gene therapy market and who are the key players?
• What is the degree of competition in the India cell and gene therapy market? 

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the India cell and gene therapy market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the India cell and gene therapy market.
• Porter's Five Forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the India cell and gene therapy industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.